

# Nathan T Connell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9144489/publications.pdf>

Version: 2024-02-01

73  
papers

1,246  
citations

516710

16  
h-index

395702

33  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1551  
citing authors

#	ARTICLE	IF	CITATIONS
1	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 280-300.	5.2	246
2	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 301-325.	5.2	152
3	VTE in ICU Patients With COVID-19. <i>Chest</i> , 2020, 158, 2130-2135.	0.8	76
4	Coagulopathy of COVID-19 and antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, .	3.8	72
5	Fostamatinib for the treatment of chronic immune thrombocytopenia. <i>Blood</i> , 2019, 133, 2027-2030.	1.4	64
6	Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. <i>American Journal of Clinical Pathology</i> , 2021, 155, 364-375.	0.7	61
7	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987472.	2.5	50
8	Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. <i>Transfusion</i> , 2016, 56, 354-359.	1.6	37
9	Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. <i>Pharmacotherapy</i> , 2016, 36, e160-e165.	2.6	35
10	Splenosis and sepsis: The born-again spleen provides poor protection. <i>Virulence</i> , 2011, 2, 4-11.	4.4	34
11	Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. <i>JAAD Case Reports</i> , 2022, 23, 15-19.	0.8	33
12	An international survey to inform priorities for new guidelines on von Willebrand disease. <i>Haemophilia</i> , 2020, 26, 106-116.	2.1	32
13	Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1576-1578.	6.0	22
14	Transfusion Medicine. <i>Primary Care - Clinics in Office Practice</i> , 2016, 43, 651-659.	1.6	19
15	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	1.5	17
16	Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans. <i>Blood Advances</i> , 2019, 3, 3278-3286.	5.2	17
17	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71.	0.5	17
18	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 62-71.	5.2	17

#	ARTICLE	IF	CITATIONS
19	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020, 98, 106459.	0.8	16
20	The role of hematologists in a changing United States health care system. <i>Blood</i> , 2015, 125, 2467-2470.	1.4	15
21	Prechemotherapy Education: Reducing Patient Anxiety Through Nurse-Led Teaching Sessions. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 76-82.	0.6	15
22	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. <i>Blood Advances</i> , 2022, 6, 228-237.	5.2	15
23	International survey on <i>Helicobacter pylori</i> testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 287-296.	3.8	13
24	Pregnancy outcomes in inherited bone marrow failure syndromes. <i>Blood</i> , 2017, 130, 1671-1674.	1.4	12
25	Acquired von Willebrand Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1103-1116.	2.2	12
26	Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. <i>Thrombosis Research</i> , 2017, 150, 53-58.	1.7	9
27	Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism. <i>Blood</i> , 2015, 126, 746-746.	1.4	9
28	Ravulizumab: a complementary option for PNH. <i>Blood</i> , 2019, 133, 503-504.	1.4	8
29	Systems-based hematology: highlighting successes and next steps. <i>Blood Advances</i> , 2020, 4, 4574-4583.	5.2	8
30	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	1.7	8
31	Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors. <i>Anti-Cancer Drugs</i> , 2018, 29, 919-923.	1.4	7
32	Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 382-386.	2.1	7
33	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. <i>Blood Advances</i> , 2022, 6, 121-128.	5.2	7
34	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. <i>Blood Advances</i> , 2021, 5, 5023-5031.	5.2	6
35	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	1.4	6
36	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	5.2	5

#	ARTICLE	IF	CITATIONS
37	Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System. <i>JCO Oncology Practice</i> , 2022, 18, e564-e573.	2.9	5
38	Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. <i>Haemophilia</i> , 2022, 28, 373-387.	2.1	5
39	Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 267-269.	1.0	4
40	<i>Klebsiella pneumoniae</i> endophthalmitis with associated hepatic abscess. <i>Journal of Hospital Medicine</i> , 2007, 2, 442-444.	1.4	3
41	The Spleen and Its Disorders. , 2018, , 2313-2327.		3
42	Venous thromboembolism in the hormonal milieu. <i>Current Opinion in Hematology</i> , 2020, 27, 327-332.	2.5	3
43	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12521.	2.3	3
44	To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin. <i>Thrombosis Research</i> , 2022, 218, 199-200.	1.7	3
45	Diversity, Equity, and Inclusion in Hematology and Oncology Fellowship Programs. <i>Blood</i> , 2021, 138, 2977-2977.	1.4	3
46	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 3735-3745.	5.2	3
47	Response to "The 2021 von Willebrand disease guidelines: Clarity and controversy" <i>Haemophilia</i> , 2022, 28, 371-372.	2.1	3
48	Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support. <i>Blood Advances</i> , 2023, 7, 3058-3068.	5.2	3
49	Does My Patient Have a Life- or Limb-Threatening Thrombocytopenia?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 369-382.	2.2	2
50	Oxaliplatin Induced Immune Thrombocytopenia in Patients with Oxaliplatin Hypersensitivity: Implications for Desensitization. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB41.	2.9	2
51	Plasmacytoma presenting as jugular foramen tumor in a young woman with multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 728-732.	4.1	2
52	Taken the wrong way, a complement becomes catastrophic. <i>Blood</i> , 2020, 135, 233-234.	1.4	2
53	Use of Social Media in the Practice of Medicine. <i>American Journal of Medicine</i> , 2021, , .	1.5	2
54	Treatment of Acquired Hemophilia a with Rituximab and Emicizumab. <i>Blood</i> , 2020, 136, 18-19.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Assessment of the effectiveness of a prechemotherapy teaching session: A Brown University Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 260-260.	1.6	2
56	Occam's Razor for Severe B12 Deficiency. American Journal of Medicine, 2022, , .	1.5	2
57	Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism. Rhode Island Medical Journal (2013), 2015, 98, 32-6.	0.2	2
58	von Willebrand disease (VWD) and BATs: How do they connect and why should I care?. Haemophilia, 2022, 28, .	2.1	2
59	How to manage bleeding disorders in aging patients needing surgery. Hematology American Society of Hematology Education Program, 2021, 2021, 529-535.	2.5	2
60	Mentorship Experiences Among Second-Year U.S. Hematology/Oncology Fellows in the 2019 ASH Hematology/Oncology Fellows Survey. Blood, 2019, 134, 2124-2124.	1.4	1
61	Cost-Effectiveness of Long-Term Prophylaxis Versus on-Demand Treatment with Von Willebrand Factor Concentrate in Severe Inherited Von Willebrand Disease. Blood, 2020, 136, 4-5.	1.4	1
62	Alphabet soup: RAEB, HMA, DOE, and AFOP. Medicine and Health, Rhode Island, 2010, 93, 385-6.	0.1	1
63	Update on pregnancy-associated venous thromboembolism. Thrombosis Update, 2022, 8, 100107.	0.9	1
64	HIT the price point with fondaparinux. Blood, 2016, 128, 3019-3020.	1.4	0
65	Which â€™roid is all the rage?. Blood, 2016, 127, 273-273.	1.4	0
66	Factoring in the missing link. American Journal of Hematology, 2017, 92, 110-113.	4.1	0
67	Sideroblastic Anemias. , 0, , 44-47.		0
68	Inherited Bleeding Disorders. Hematology/Oncology Clinics of North America, 2021, 35, xiii-xiv.	2.2	0
69	Inherited Bleeding Disorders. Hematology/Oncology Clinics of North America, 2021, 35, i.	2.2	0
70	Correlation Of ADAMTS13 Activity With Baseline Characteristics and Management Patterns In Patients With Suspected Thrombotic Thrombocytopenic Purpura In The State Of Rhode Island. Blood, 2013, 122, 3556-3556.	1.4	0
71	Human Immunodeficiency Virus-Associated Malignancies. , 0, , 169-183.		0
72	Anticoagulation Use and Outcomes Among Patients with Atrial Fibrillation and Von Willebrand Disease. Blood, 2021, 138, 590-590.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Splenic cyst manifesting as gastric outlet obstruction. <i>Medicine and Health, Rhode Island</i> , 2011, 94, 218.	0.1	0